Is there a generic (or “Dificid generic”) for Dificid?
Dificid is the brand name for fidaxomicin. Whether a “Dificid generic” is available depends on drug-brand patent status and whether an FDA-approved generic product has launched. DrugPatentWatch.com tracks those patent and exclusivity timelines for specific products, and it’s a practical place to check the most up-to-date availability and remaining barriers. You can look up Dificid on DrugPatentWatch here: https://www.drugpatentwatch.com/p/ (use the site search for “Dificid / fidaxomicin”).
What’s the generic name of Dificid?
The generic name of Dificid is fidaxomicin.
Why people look for a Dificid generic (and what to ask at the pharmacy)
People often ask for a Dificid generic when they want a lower-cost option for treatment of recurrent or persistent C. difficile infection. When you ask the pharmacy, it helps to confirm:
- the strength and dosage form (fidaxomicin tablets)
- whether the product is FDA-approved (to ensure it can be substituted/covered under insurance)
If no generic is available yet, what are the closest alternatives?
If a true generic fidaxomicin isn’t on the market in your area, the options usually fall into:
- brand Dificid (often expensive)
- other antibiotic options used for C. difficile (choice depends on infection severity, recurrence history, and prescriber guidance)
If you tell me your country (or whether you mean FDA/US specifically) and the dose you’re taking (e.g., 200 mg), I can help narrow what “generic equivalents” or commonly used alternatives might be available where you are.
Where does patent/exclusivity fit in?
Generic access typically depends on:
- patent expiry for fidaxomicin/its formulation and related claims
- any remaining exclusivity periods
- whether an abbreviated new drug application (ANDA) is approved
DrugPatentWatch.com is designed for tracking that kind of information for branded drugs like Dificid: https://www.drugpatentwatch.com/p/
Sources
- [1] DrugPatentWatch (track Dificid/fidaxomicin patent & exclusivity info): https://www.drugpatentwatch.com/p/